Coloplast A/S
OTC:CLPBY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (23.6), the stock would be worth $12.26 (87% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12.6 | $6.56 |
0%
|
| 3-Year Average | 23.6 | $12.26 |
+87%
|
| 5-Year Average | 25 | $12.95 |
+97%
|
| Industry Average | 15 | $7.76 |
+18%
|
| Country Average | 10.3 | $5.34 |
-19%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$128.3B
|
/ |
Jan 2026
kr9.1B
|
= |
|
|
$128.3B
|
/ |
Sep 2026
kr9.4B
|
= |
|
|
$128.3B
|
/ |
Sep 2027
kr10.1B
|
= |
|
|
$128.3B
|
/ |
Sep 2028
kr10.9B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| DK |
|
Coloplast A/S
OTC:CLPBY
|
95.4B USD | 12.6 | 23.8 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY | 27.9 | 38.5 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.4B CHF | 14.5 | 37.7 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
14B USD | 14.5 | 33.3 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 11.9 | 34.3 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 16.9 | -15.7 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
880.1B JPY | 23.5 | 49.8 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -81.4 | -36.4 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.4B USD | 14.7 | 22.9 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
36.4B CNY | 31.5 | 21.4 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 5.1 |
| Median | 10.3 |
| 70th Percentile | 16.4 |
| Max | 10 882.4 |
Other Multiples
Coloplast A/S
Glance View
Coloplast A/S, headquartered in Humlebæk, Denmark, has a storied history that dates back to 1954 when a nurse, Elise Sørensen, identified a crucial need in the healthcare sector. Her sister had undergone ostomy surgery, and the lack of appropriate post-operative care products inspired Sørensen to design the world’s first adhesive ostomy bag. This innovation laid the groundwork for Coloplast's trajectory in the healthcare industry. Today, the company has expanded its focus to include ostomy care, continence care, wound and skin care, and interventional urology. With a commitment to improving patients' quality of life, Coloplast has become a leader in designing and manufacturing products that not only highlight practicality but also embody comfort and discretion. Coloplast generates revenue through a business model that emphasizes product innovation and direct engagement with healthcare providers and patients. The company invests significantly in research and development to improve and widen its product offerings continuously. It operates globally, distributing its products directly and via partnerships with hospitals, clinics, and healthcare professionals. By maintaining an attentive approach to user experience and incorporating customer feedback into its development processes, Coloplast ensures its portfolio aligns with the actual needs of its users. This user-centered strategy not only enhances customer loyalty but also fortifies the company’s market position, driving its financial success.
